Business context and reporting period
The supplied filing is Oncocyte Corporation’s unaudited Form 10-Q for the quarter and six months ended June 30, 2023; it does not identify Insight Molecular Diagnostics Inc. as the registrant. Oncocyte is a precision diagnostics company developing and commercializing DetermaIO, VitaGraft and DetermaCNI, and providing pharmaceutical services.
Following the February 2023 sale of 70% of Razor Genomics, DetermaRx operations are reported as discontinued operations. Oncocyte retained approximately 30% of Razor and transferred the related DetermaRx assets and liabilities; the sale generated no monetary consideration, but eliminated Oncocyte’s DetermaRx development and commercialization costs.
Unless otherwise indicated, financial amounts below are in U.S. dollars; statement amounts are reported in thousands and are shown here in millions. Per-share and share amounts in the filing reflect a subsequent 1-for-20 reverse split, effective July 24, 2023.
Financial performance and position
| Metric | Three months ended June 30, 2023 | Six months ended June 30, 2023 | Comparable 2022 period |
|---|---|---|---|
| Continuing-operations revenue | $0.463 million | $0.760 million | $0.237 million and $0.617 million, respectively |
| Gross profit | $0.272 million; 59% margin | $0.282 million; 37% margin | $0.031 million; 13% margin and $0.278 million; 45% margin, respectively |
| Loss from operations | $8.294 million | $2.444 million | $1.626 million and $4.643 million, respectively |
| Net loss | $8.333 million | $5.300 million | $8.300 million and $18.591 million, respectively |
| Net loss per share | $1.07 | $0.83 | $1.48 and $3.63, respectively |
- Revenue from continuing operations increased 95% in Q2 and 23% in the first half, mainly from higher Pharma Services activity. Pharma Services represented 94% of Q2 revenue and 62% of first-half revenue. One customer accounted for 68% of Q2 consolidated revenue, a material concentration.
- Quarterly operating loss worsened substantially year over year, largely because the contingent-consideration fair-value line shifted from a $6.359 million gain in Q2 2022 to a $1.795 million loss in Q2 2023. For the first half, a $16.512 million fair-value gain helped reduce reported net loss; it is a noncash accounting item, not operating cash generation.
- First-half operating expenses included $4.562 million of research and development, $1.500 million of sales and marketing, and $6.943 million of general and administrative expense. The company also recorded a $4.950 million intangible-asset impairment and $1.283 million loss on disposal and held-for-sale assets.
- Net cash used in operating activities was $16.504 million in the first half, compared with $24.524 million in 2022. Investing activities provided $0.123 million; financing activities provided $12.246 million, primarily from the April 2023 common-stock offering.
- At June 30, cash and cash equivalents were $17.368 million, restricted cash was $1.700 million, and marketable equity securities were $0.530 million. Total assets were $87.540 million, total liabilities $39.215 million, and shareholders’ equity $43.600 million. Cash, cash equivalents and restricted cash totaled $19.068 million.
- The filing reports no outstanding bank loan principal; it had paid off its Silicon Valley Bank loan. Lease liabilities totaled approximately $3.135 million. Series A redeemable convertible preferred stock was recorded at $4.725 million, with a $5.140 million aggregate liquidation preference and a 6% cumulative dividend.
Material changes versus the prior comparable period
- Q2 continuing-operations revenue grew from $0.237 million to $0.463 million, while Q2 net loss was broadly flat at $8.333 million versus $8.300 million. Q2 2022 included a $6.936 million loss from discontinued operations; Q2 2023 had none.
- First-half net loss improved to $5.300 million from $18.591 million. The comparison reflects lower losses from discontinued Razor operations, reduced general and administrative expense, and a larger contingent-consideration fair-value gain; it does not indicate positive operating cash flow.
- First-half general and administrative expense declined 37% to $6.943 million, while sales and marketing expense rose 282% to $1.500 million, reflecting increased commercial activity, particularly for transplantation and oncology products.
- Common shares outstanding increased to approximately 8.241 million from 5.932 million at year-end 2022, including shares issued in the April 2023 financing. The reverse split occurred after quarter-end; authorized common shares remained 230 million.
Outlook, risks and unusual items
- Going concern: Management concluded substantial doubt exists about the company’s ability to continue as a going concern for at least 12 months after issuance of the financial statements. It expects continued operating losses and negative cash flows and says additional capital is needed. Planned equity financing and spending reductions are not considered probable enough to alleviate the doubt; further reductions or delays may be required if financing is unavailable.
- Liquidity constraints: Management said the April 2023 workforce reduction was intended to extend cash runway into 2024, but that estimate is not assurance of adequate funding. Series A preferred-stock terms include an $8 million minimum unrestricted, unencumbered cash requirement and require cash redemption by April 8, 2024, subject to specified earlier triggers. The company redeemed approximately $1.1 million of preferred stock in April 2023.
- Product and reimbursement risk: DetermaIO was available for biopharma development and research use only as of June 30, while the company was completing clinical development and planning commercialization. VitaGraft and DetermaCNI development, future clinical outcomes, regulatory progress, and Medicare or other payer coverage and reimbursement remain uncertain.
- Strategic and asset changes: Management shifted its strategy toward fewer studies and research-use-only sales, contributing to a $4.950 million impairment of DetermaIO-related intangible assets. Laboratory equipment sales and write-downs also resulted in disposal and held-for-sale losses. The company terminated its Thermo Fisher collaboration in February 2023 and reported $0.749 million owed for certain development costs.
- Other risks and subsequent events: Nasdaq notified the company on August 8, 2023 that it had regained compliance with the minimum bid-price requirement. The July 24 reverse split may reduce trading liquidity and, because authorized shares were unchanged, increases potential future dilution. The filing also notes that commercial success depends on generating revenue, securing reimbursement, and obtaining additional financing.
- The company reported no material litigation and stated that previously identified internal-control material weaknesses were remediated; management considered disclosure controls effective at June 30, 2023.
Important facts for investors to verify
- Confirm the intended issuer: the provided filing names Oncocyte Corporation, not Insight Molecular Diagnostics Inc.
- Review the latest cash burn, financing availability, and any updated assessment of the disclosed going-concern uncertainty.
- Check the timing and terms of Series A preferred-stock dividends, redemption obligations, and compliance with its minimum-cash covenant.
- Track Pharma Services revenue quality and customer concentration, including the contribution and renewal status of the customer responsible for 68% of Q2 revenue.
- Verify clinical, commercialization, and reimbursement milestones for DetermaIO, VitaGraft and DetermaCNI, and assess whether the company’s revised strategy changes expected investment needs.
- Assess dilution and trading-liquidity implications of the April 2023 equity issuance, outstanding warrants and preferred stock, and the reverse split with unchanged authorized shares.